2025
conference-abstract
OpenAlex
Christoph Herbel, Manuel Martinez-Osuna, Larissa Steiner, Maria Bethke et autres
Abstract Treatment options for ovarian cancer patients are limited, highlighting a significant unmet need for targeted, durable, and effective therapies. In recent years, adoptive cell transfer therapies have made tremendous progress in the past years. Genetically engineered T cells expressing a chimeric …
de
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Maria Bethke, Pierre Abramowski, Miriam Droste, André Felsberger et autres
CAR T cell therapy has been an effective treatment option for hematological malignancies. However, the therapeutic potential of CAR T cells can be reduced by several constraints, partly due to immunogenicity and toxicities. The lack of established workflows enabling thorough evaluation of …
de
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Julie Daigre, Manuel Martinez-Osuna, Maria Bethke, Larissa Steiner et autres
Treatment options for ovarian cancer patients are limited, and a high unmet clinical need remains for targeted and long-lasting, efficient drugs. Genetically modified T cells expressing chimeric antigen receptors (CAR), are promising new drugs that can be directed towards a defined target …
de
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Christoph Herbel, Julie Daigre, Manuel Martinez-Osuna, Maria Bethke et autres
Abstract Purpose: Treatment of ovarian cancer remains challenging. A high unmet clinical need for targeted, efficient, and persisting drugs still is a major issue for clinicians and patients diagnosed with ovarian cancer, particularly platinum-resistant and-refractory, recurrent disease. Genetically modified T cells expressing …
de
(code pays fourni par la source)